CHAPEL HILL, N.C., July 17, 2012 /PRNewswire-Asia/ -- The University of North Carolina at Chapel Hill's Frank Hawkins Kenan Institute of Private Enterprise( http://www.kenan-flagler.unc.edu/kenan-institute ) has appointed Joseph M. DeSimone as its new director.
DeSimone is the Chancellor's Eminent Professor of Chemistry at UNC( http://www.unc.edu ) and William R. Kenan Jr. Distinguished Professor of Chemical Engineering at NC State University and of Chemistry at UNC.
He replaces John D. Kasarda, who retired in June after serving as the director of the Kenan Institute for 22 years.
"We are very pleased to welcome Joseph DeSimone to the Kenan Institute," said James W. Dean Jr., dean of UNC Kenan-Flagler. "He is a world-renowned scholar in his field. As an innovative entrepreneur, he is applying his research to design novel nanomedicines for cancer therapy and to improve vaccines and drug delivery mechanisms. He is the perfect leader to continue the institute's cutting-edge research and collaboration with business and communities to create positive local and global change."
"Rooted in the visionary leadership of Frank Hawkins Kenan and John Kasarda, the Kenan Institute is central to UNC's continued leadership as an entrepreneurial university in the 21st century," DeSimone said. "I am forever grateful for the unbelievably strong support that I and the university continue to receive from the Kenan family. We are uniquely positioned to leverage the intellectual capital we have right here on campus, join it with some of the best and brightest minds from around the globe, and develop innovative market-based solutions to some of the most pressing global challenges of our time, including poverty, health, education, energy, sustainable development and economic growth. I am thrilled to have the opportunity to help drive the institute forward at this critical juncture."
The Kenan Institute, part of UNC's Kenan-Flagler Business School( http://www.kenan-flagler.unc.edu/kenan-institute ), pursues cutting-edge research, educational programs and public policy initiatives in the areas of entrepreneurship, economic development and global competitiveness.
DeSimone's research focuses on applying lithographic fabrication technologies from the computer industry for the design and synthesis of new medicines and vaccines. He has almost 300 publications, is an inventor on more than 130 patents and has more than 100 patents pending. In 2004, DeSimone and his students invented a new technology to create nanoparticles using a process they coined as PRINT (Particle Replication In Non-wetting Templates).
With PRINT, DeSimone and his team were the first to successfully adapt manufacturing techniques from the computer industry to make advances in medicine, including improved approaches to cancer treatment and diagnosis. Other projects include developing nanoparticle vaccines for infectious diseases, vaccines for cancer and particles that mimic red blood cells.
DeSimone co-founded Liquidia Technologies( http://www.liquidia.com ), a Triangle-based nanotechnology company, to further develop the PRINT technology. Liquidia has its first product a nanoparticle flu vaccine in clinical trials.
In June, Liquidia announced the initiation of a multiyear collaboration with GlaxoSmithKline, potentially worth several hundred million dollars. The efforts of the two companies as a result of this agreement could lead to the development of multiple life-saving health-care products.
Read more from the original source:
Kenan Institute Appoints Joseph DeSimone as New Director